BREAKWATER Trial

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

The CHMP has sent a positive opinion to the European Commission after Phase 3 BREAKWATER showed higher response rates alongside longer survival for patients with the BRAFV600E mutation.